High-risk early HR-positive breast cancer
Most hormone-driven breast cancers are cured with surgery, radiotherapy and five to ten years of endocrine tablets. Women whose tumours are larger, higher grade or have reached the lymph nodes face a higher risk of relapse: two to three years of a CDK4/6 inhibitor added to endocrine therapy cuts recurrence, and genomic tests such as Oncotype DX and MammaPrint decide who also needs chemotherapy.
Overview
High-risk early disease is defined clinically and genomically. monarchE took node-positive tumours with four or more nodes, or one to three nodes with grade 3, a tumour of 5 cm or more or Ki-67 of 20 percent or more; NATALEE widened the net to stage II and III disease including node-negative stage IIA tumours with high-risk features. Genomic assays sort the rest: TAILORx showed that women over 50 with node-negative tumours and an Oncotype DX recurrence score of 11 to 25 gain nothing from chemotherapy (nine-year invasive disease-free survival 83.3 percent without and 84.3 percent with), RxPONDER showed the same for postmenopausal women with one to three positive nodes and a score up to 25 while premenopausal women still benefited, and MINDACT showed that clinically high-risk tumours with a low MammaPrint score reach 94.7 percent five-year distant metastasis-free survival without chemotherapy.
Endocrine therapy is the backbone. Five years of tamoxifen cuts recurrence and breast cancer death for at least fifteen years, aromatase inhibitors do slightly better in postmenopausal women, and the SOFT and TEXT trials showed that premenopausal women at higher risk do best with ovarian function suppression plus exemestane, with twelve-year disease-free survival of 80.5 percent against 75.9 percent for suppression plus tamoxifen; adding suppression to tamoxifen improved overall survival in the women who had needed chemotherapy. ATLAS and aTTom showed that ten years of tamoxifen beats five, and MA.17 that letrozole after five years of tamoxifen reduces late recurrence, so extended therapy to seven to ten years is offered in node-positive disease at the price of bone loss, joint pain and adherence that falls with every year.
The CDK4/6 inhibitors changed the adjuvant standard. monarchE randomised 5,637 women to two years of abemaciclib with endocrine therapy or endocrine therapy alone and cut invasive recurrence (hazard ratio 0.68), with the gap still widening at five years; NATALEE randomised 5,101 to three years of ribociclib with an aromatase inhibitor (hazard ratio 0.75) and won approval in September 2024. Palbociclib failed twice in the same setting (PALLAS, PENELOPE-B), a reminder that the class does not behave as one drug. Adjuvant olaparib for a year adds survival for germline BRCA carriers (OlympiA), adjuvant giredestrant improved invasive disease-free survival in lidERA in 2025, camizestrant switching is being tested in CAMBRIA, and circulating tumour DNA is being studied to find the women whose late relapse is coming.
State of the art
- Two adjuvant CDK4/6 inhibitors, abemaciclib and ribociclib, are approved for high-risk disease on the strength of trials of more than five thousand women each.
- Genomic assays have moved most node-negative and many node-positive postmenopausal women off chemotherapy without loss of cure.
- Ovarian suppression with an aromatase inhibitor is the standard for higher-risk premenopausal women, and the POSITIVE study showed endocrine therapy can be paused safely to attempt pregnancy.
- Oral oestrogen receptor degraders are entering the adjuvant setting after lidERA.
Red cards
From the labels and guidelines behind the standard of care. Your team's thresholds win.- Emergency services nowBlood clot (tamoxifen and others)
A swollen painful calf, or sudden breathlessness with chest pain; the tamoxifen boxed warning covers pulmonary embolism and stroke.
- Emergency services nowFainting or palpitations (ribociclib)
Fainting, dizziness or an irregular heartbeat; QT prolongation is a labelled warning and ECGs are checked in the first cycles.
- Emergency services nowBlood clot
A swollen painful calf, or sudden breathlessness with chest pain; venous thromboembolism including pulmonary embolism is a labelled warning.
- Check before combiningRibociclib with Tamoxifen: major interaction
Additive QT prolongation; ribociclib is not recommended with tamoxifen.. Use an aromatase inhibitor or fulvestrant instead.
- Check before combiningFood and drink: Abemaciclib
Avoid grapefruit. Diarrhoea: start loperamide at the first loose stool.
- Check before combiningFood and drink: Exemestane
Take after a meal.
See all on the product pages:AbemaciclibExemestaneGoserelin / leuprolide (ovarian function suppression)Letrozole (and other aromatase inhibitors)OlaparibRibociclibTamoxifen·Printable cards in the navigator
Anatomy and lymph node drainage
- Ducts (most cancers start here)
- Lobules (lobular carcinoma; phyllodes tumours arise from the surrounding stroma)
- Upper outer quadrant (commonest site)
- Nipple-areola
- Nodes: axillary level I
- Nodes: axillary level II-III
- Nodes: internal mammary
- Nodes: supraclavicular
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
- Ducts (most cancers start here)Luminal A-like, node-positive disease (genomic assay decides chemotherapy) · Luminal B-like disease with high grade or high Ki-67 (chemotherapy and CDK4/6 inhibitor candidates)
- Lobules (lobular carcinoma; phyllodes tumours arise from the surrounding stroma)
- Upper outer quadrant (commonest site)
- Nipple-areola
- axillary level I
- axillary level II-III
- internal mammary
- supraclavicular
Same organ: Triple-negative breast cancer (TNBC), Breast cancer (all types), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS), HR-positive metastatic breast cancer after CDK4/6 inhibitors, HER2-low and HER2-ultralow metastatic breast cancer, Early HER2-positive breast cancer, HER2-positive breast cancer with brain metastases, Early triple-negative breast cancer, Metastatic triple-negative breast cancer, Inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumour of the breast
Hormone receptor-positive, HER2-negative tumours are about seven in ten breast cancers and most are cured; the high-risk minority with node involvement, large size or high grade account for most of the relapses, which in this subtype can arrive ten or twenty years after diagnosis.
- Liquid biopsy (ctDNA)Standard of care
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Genomic assay on node-negative and one to three node-positive tumours; chemotherapy for a high recurrence score, for premenopausal women with node-positive disease and a score up to 25, and for clinically high-risk tumours without a low genomic score.
Aromatase inhibitor for postmenopausal women; tamoxifen, or ovarian function suppression with an aromatase inhibitor for premenopausal women at higher risk (SOFT and TEXT); five years, extended to seven to ten in node-positive disease.
Abemaciclib for two years (monarchE, node-positive high-risk disease) or ribociclib for three years (NATALEE, stage II to III) alongside the aromatase inhibitor.
One year of adjuvant olaparib after chemotherapy for high-risk disease (OlympiA).
Breast-conserving surgery with hypofractionated whole-breast radiotherapy or mastectomy, sentinel node biopsy, and regional nodal irradiation when nodes are involved.
Zoledronic acid or denosumab during aromatase inhibitor therapy in postmenopausal women reduces fractures, and bisphosphonates also reduce bone recurrence.
Subtypes & biomarkers
top- Luminal A-like, node-positive disease (genomic assay decides chemotherapy)
- Luminal B-like disease with high grade or high Ki-67 (chemotherapy and CDK4/6 inhibitor candidates)
- Node-positive disease with four or more nodes (monarchE population)
- Stage II node-negative disease with high-risk features (NATALEE population)
- Premenopausal disease (ovarian function suppression, SOFT and TEXT)
- Late recurrence risk beyond five years (extended endocrine therapy)
- Oestrogen and progesterone receptor percentage
- HER2-negative status (HER2-low noted for later lines)
- Tumour grade and Ki-67
- Nodal stage and tumour size (monarchE and NATALEE eligibility)
- Oncotype DX recurrence score (TAILORx, RxPONDER)
- MammaPrint 70-gene risk (MINDACT)
- Menopausal status and oestradiol during ovarian suppression
- Germline BRCA1 and BRCA2 (OlympiA eligibility)
How often this target appears
- 1977Tamoxifen approved
- 1998EBCTCG overview: five years of tamoxifen cuts recurrence and death
- 2004MA.17: letrozole after five years of tamoxifen reduces late recurrence
- 2013ATLAS: ten years of tamoxifen beats five
- 2014SOFT and TEXT: ovarian suppression with exemestane in premenopausal women
- 2016MINDACT: genomic low-risk women can skip chemotherapy
- 2018TAILORx: no chemotherapy benefit for intermediate recurrence scores
- 2020monarchE: adjuvant abemaciclib; RxPONDER in node-positive disease
- 2023NATALEE: adjuvant ribociclib in stage II to III disease
- 2025lidERA: adjuvant giredestrant improves invasive disease-free survival
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
All 20 changes by month →- 2026-09-17This recordHigh-risk early HR-positive breast cancerFacts on this page last checked
When this page itself was last checked or edited.
- 2025Trial resultlidERAlidERA reported
iDFS ~30% relative reduction (HR ~0.
- 2025MilestonelidERAlidERA: adjuvant giredestrant improves invasive disease-free survival
A milestone in how this cancer is treated.
- 2023Trial resultNATALEENATALEE reported
iDFS HR 0.
- 2023MilestoneNATALEENATALEE: adjuvant ribociclib in stage II to III disease
A milestone in how this cancer is treated.
- 2021Trial resultOlympiAOlympiA reported
iDFS HR 0.
What is in development for High-risk early HR-positive breast cancer, drawn from the whole corpus: 13 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Drugs in phase 3 · 1
Technologies being tested · 1
Trials under way · 2
- CAMBRIA-1 & CAMBRIA-2 · phase 3 · AstraZeneca
- Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) · phase 3 · Merck Sharp & Dohme LLC
Trials reported · 9
- lidERA · phase 3 · 2025 · positive
- MINDACT · phase 3 · 2016 · positive
- monarchE · phase 3 · 2020 · positive
- NATALEE · phase 3 · 2023 · positive
- OlympiA · phase 3 · 2021 · positive
- PALLAS & PENELOPE-B · phase 3 · 2020 · negative
- RxPONDER (SWOG S1007) · phase 3 · 2020 · positive
- SOFT & TEXT · phase 3 · 2014 · positive
- TAILORx · phase 3 · 2018 · positive
Open problems and what is being done
No test yet identifies the women whose relapse will come after ten years, when endocrine therapy has stopped.
and how the field plans to fix it →What is being done about thisRecurrence and residual diseaseAvailable now- ArteraAI BreastApproved
- Goserelin / leuprolide (ovarian function suppression)Approved
- Liquid biopsy (ctDNA)Standard of care
- MRD / molecular residual disease testingEstablished
- TamoxifenApproved
In trials- CAMBRIA-1 & CAMBRIA-2Active
- lidERAPositive
- monarchEPositive
- NATALEEPositive
- OlympiAPositive
- SOFT & TEXTPositive
Ideas and roadmapsNothing recorded yet.
Also on OnCo: Treatment journeys · Survivorship planner.
Two to three years of a CDK4/6 inhibitor is costly and its overall survival benefit is not yet proven.
Adherence to endocrine therapy falls to about half by five years because of joint pain, hot flushes and sexual side effects.
and how the field plans to fix it →What is being done about thisSide effects and quality of lifeAvailable now- Hypofractionated radiotherapyEstablished
- Sentinel lymph node biopsyStandard of care
In trialsNothing recorded yet.
Ideas and roadmapsNothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Premenopausal women with node-positive disease still gain from chemotherapy in RxPONDER, and whether ovarian suppression could replace it is unanswered.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Expert centres
topExpert centres
| United Kingdom | none recorded | 0 | 1,026 | 17,745 | #7 | ||
Baltimore · cancer center | United States | 0 | 2,955 | 41,449 | #10 | ||
Milan · cancer center Programme: Breast surgery, Breast medical oncology | Italy | none recorded | 0 | 1,246 | 21,746 | #11 | |
Newcastle, NSW · consortium | Australia | none recorded | 2 | 10 | 542 | - | |
London · hospital Programme: Breast cancer and PARP inhibitors | United Kingdom | none recorded | 1 | 693 | 7,168 | - | |
Philadelphia, PA · consortium | United States | none recorded | 1 | 87 | 2,130 | none recorded | - |
Bern · consortium | Switzerland | none recorded | 1 | 82 | 2,450 | - | |
Bronx, NY · cancer center Programme: Breast cancer (TAILORx) | United States | 1 | 49 | 182 | - | ||
Brussels · consortium | Belgium | none recorded | 1 | 43 | 1,085 | none recorded | - |
Vienna · consortium | Austria | none recorded | 1 | 32 | 166 | - | |
Atlanta, GA · cancer center Programme: Breast cancer (RxPONDER) | United States | 1 | not matched | - | - | ||
Shanghai · hospital | China | none recorded | 0 | 2,872 | 31,534 | - | |
London · hospital | United Kingdom | none recorded | 0 | 2,376 | 28,940 | - | |
Beijing · hospital | China | none recorded | 0 | 1,784 | 18,230 | - | |
Miami, FL · cancer center | United States | 0 | 1,607 | 15,145 | - |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with High-risk early HR-positive breast cancer but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
Questions to ask
topQuestions to ask your oncologist about High-risk early HR-positive breast cancer
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Oestrogen and progesterone receptor percentage, HER2-negative status, Tumour grade and Ki-67, Nodal stage and tumour size, Oncotype DX recurrence score), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Luminal A-like, node-positive disease, Luminal B-like disease with high grade or high Ki-67, Node-positive disease with four or more nodes.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Deciding on chemotherapy
- For my situation (deciding on chemotherapy), which of the standard options do you recommend and why?Why: Guideline options include: Genomic assay on node-negative and one to three node-positive tumours; chemotherapy for a high recurrence score, for premenopausal women with node-positive disease and a score up to 25, and for clinically high-risk tumours without a low genomic score.
- Am I a candidate for Oncotype DX, MammaPrint (70-gene signature), and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of TAILORx and RxPONDER (SWOG S1007) apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Endocrine therapy
- For my situation (endocrine therapy), which of the standard options do you recommend and why?Why: Guideline options include: Aromatase inhibitor for postmenopausal women; tamoxifen, or ovarian function suppression with an aromatase inhibitor for premenopausal women at higher risk (SOFT and TEXT); five years, extended to seven to ten in node-positive disease.
- Am I a candidate for Letrozole (and other aromatase inhibitors), Exemestane, Tamoxifen or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of SOFT & TEXT apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Adjuvant CDK4/6 inhibitor
- For my situation (adjuvant cdk4/6 inhibitor), which of the standard options do you recommend and why?Why: Guideline options include: Abemaciclib for two years (monarchE, node-positive high-risk disease) or ribociclib for three years (NATALEE, stage II to III) alongside the aromatase inhibitor.
- Am I a candidate for Abemaciclib, Ribociclib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of monarchE and NATALEE apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Germline BRCA carriers
- For my situation (germline brca carriers), which of the standard options do you recommend and why?Why: Guideline options include: One year of adjuvant olaparib after chemotherapy for high-risk disease (OlympiA).
- Am I a candidate for Olaparib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of OlympiA apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Local therapy
- For my situation (local therapy), which of the standard options do you recommend and why?Why: Guideline options include: Breast-conserving surgery with hypofractionated whole-breast radiotherapy or mastectomy, sentinel node biopsy, and regional nodal irradiation when nodes are involved.
Bone protection
- For my situation (bone protection), which of the standard options do you recommend and why?Why: Guideline options include: Zoledronic acid or denosumab during aromatase inhibitor therapy in postmenopausal women reduces fractures, and bisphosphonates also reduce bone recurrence.
- Am I a candidate for Zoledronic acid, Denosumab, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of lidERA, CAMBRIA-1 & CAMBRIA-2, Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756), Giredestrant?Why: Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
- I read that “No test yet identifies the women whose relapse will come after ten years, when endocrine therapy has stopped”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
- I read that “Two to three years of a CDK4/6 inhibitor is costly and its overall survival benefit is not yet proven”. How does that affect my plan?Why: Open problems are where trials and second opinions matter most.
Newly diagnosed? Read the first 60 days with High-risk early HR-positive breast cancer, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
16targets
5drugs
14companies
9terms
2trials
11Latest papers
topQuery for this cancer: (TITLE:"High-risk early HR-positive breast cancer" OR ABSTRACT:"High-risk early HR-positive breast cancer" OR TITLE:"High-risk early hormone receptor-positive, HER2-negative breast cancer" OR ABSTRACT:"High-risk early hormone receptor-positive, HER2-negative breast cancer" OR TITLE:"Node-positive luminal breast cancer" OR ABSTRACT:"Node-positive luminal breast cancer" OR TITLE:"Stage II to III HR-positive breast cancer" OR ABSTRACT:"Stage II to III HR-positive breast cancer") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about High-risk early HR-positive breast cancer, not a curated reading list.
Similar pages
not linked directly; found by shared links- CancerPaget disease of the nipple
Shares Lumpectomy (breast-conserving surgery), Mastectomy, Hypofractionated radiotherapy, Tamoxifen and the tag subtype-page.
- CancerEarly triple-negative breast cancer
Shares Lumpectomy (breast-conserving surgery), Mastectomy, OlympiA, Hypofractionated radiotherapy and the tag subtype-page.
- CancerInflammatory breast cancer
Shares Mastectomy, OlympiA, Letrozole (and other aromatase inhibitors), Tamoxifen and the tag subtype-page.
- CancerHR-positive metastatic breast cancer after CDK4/6 inhibitors
Shares CAMBRIA-1 & CAMBRIA-2, Giredestrant, Camizestrant, Exemestane and the tag subtype-page.
- CancerEarly HER2-positive breast cancer
Shares Lumpectomy (breast-conserving surgery), Mastectomy, Hypofractionated radiotherapy, Sentinel lymph node biopsy and the tag subtype-page.
- CancerPhyllodes tumour of the breast
Shares Lumpectomy (breast-conserving surgery), Mastectomy and the tag subtype-page.
- CancerEndometrial cancer with no specific molecular profile
Shares Letrozole (and other aromatase inhibitors), Abemaciclib, Sentinel lymph node biopsy and the tag subtype-page.
- CancerMicrosatellite-unstable (MSI-high) gastric cancer
Shares Germline (hereditary) testing, MRD / molecular residual disease testing, Liquid biopsy (ctDNA) and the tag subtype-page.